A carregar...
First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2− Breast Cancer
Women with hormone receptor–positive, human epidermal growth factor receptor 2− negative breast cancer—the most common subtype—have new options as palbociclib and similar drugs debut. This article outlines the rationale and evidence for their use.
Na minha lista:
| Publicado no: | P T |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MediMedia USA, Inc.
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4517534/ https://ncbi.nlm.nih.gov/pubmed/26236140 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|